'Charting a new course for prostate cancer' - currying favor for docetaxel in hormone-sensitive metastatic prostate cancer

被引：6
|
作者：
Voskoboynik, Mark [1 ,2 ]
Staffurth, John [3 ]
Malik, Zafar [4 ]
Sweeney, Christopher [5 ,6 ]
Chowdhury, Simon [1 ,2 ]
机构：
[1] Guys Hosp, Dept Med Oncol, London SE1 9RT, England
[2] Sarah Cannon Res Inst UK, London, England
[3] Cardiff Univ, Inst Canc & Genet, Velindre Canc Ctr, Cardiff, S Glam, Wales
[4] Clatterbridge Canc Ctr, Bebington, Wirral, England
[5] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[6] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA
来源：
EXPERT REVIEW OF ANTICANCER THERAPY | 2014年 / 14卷 / 11期
关键词：
CHAARTED; docetaxel; hormone sensitive; metastatic prostate cancer; Sweeney; MITOXANTRONE PLUS PREDNISONE; INCREASED SURVIVAL; OPEN-LABEL; CHEMOTHERAPY; ABIRATERONE; ENZALUTAMIDE; PHASE-3; TRIAL;
D O I：
10.1586/14737140.2014.971112
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Docetaxel has an established role in the treatment of metastatic castrate-resistant prostate cancer. A number of recent treatments have been shown to improve the survival outcomes for this group of patients and many with improved toxicity profiles, bringing the role of docetaxel into question. We discuss the results and implications of the CHAARTED study that demonstrated a significant improvement in overall survival with docetaxel in metastatic hormone-sensitive prostate cancer. © Informa UK, Ltd.
引用
收藏
页码：1253 / 1256
页数：4
相关论文
共 50 条
  • [21] TITAN study: evaluation of apalutamide in patients with metastatic hormone-sensitive prostate cancer - Treatment of metastatic hormone-sensitive prostate cancer (mHSPC)
    Merseburger, Axel S.
    Suttmann, Henrik
    AKTUELLE UROLOGIE, 2021, 52 (02) : 155 - 160
  • [22] Metastatic Hormone-sensitive Prostate Cancer: Patient Selection for Prostate Radiotherapy
    Chakrabarti, Deep
    Parker, Chris C.
    EUROPEAN UROLOGY, 2024, 86 (01) : 18 - 19
  • [23] Efficacy of bi-weekly docetaxel in hormone-sensitive metastatic prostate cancer (mHSPC).
    Lombana Quinonez, Milton Alberto
    Milena Torres, Ana
    Gonzalez, Guido
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [24] Indirect comparison of abiraterone acetate and docetaxel for treatment of metastatic "hormone-sensitive" prostate cancer
    Feyerabend, S.
    Saad, F.
    Li, T.
    Ito, T.
    Diels, J.
    Van Sanden, S.
    De Porre, P.
    Roiz, J.
    Abogunrin, S.
    Fizazi, K.
    ANNALS OF ONCOLOGY, 2017, 28
  • [25] Abiraterone vs. docetaxel for metastatic hormone-sensitive prostate cancer: A microsimulation model
    Hird, Amanda E.
    Magee, Diana E.
    Cheung, Douglas C.
    Matta, Rano
    Kulkarni, Girish S.
    Nam, Robert K.
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2020, 14 (09): : E418 - E427
  • [26] Diagnosis and staging of metastatic hormone-sensitive prostate cancer
    Krausewitz, Philipp
    Ritter, Manuel
    Essler, Markus
    UROLOGIE, 2023, 62 (04): : 347 - 353
  • [27] Pros and cons of docetaxel used to treat metastatic hormone-sensitive prostate cancer: The cons
    Suzuki, Kazuhiro
    ANNALS OF ONCOLOGY, 2016, 27
  • [28] Triple therapy in metastatic hormone-sensitive prostate cancer
    Tsaur, Igor
    Mirvald, Cristian
    Surcel, Cristian
    CURRENT OPINION IN UROLOGY, 2023, 33 (06) : 452 - 457
  • [29] Approval for Zytiga® in metastatic hormone-sensitive Prostate Cancer
    Junker, Annette
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 (03) : 152 - 152
  • [30] Modern treatment of metastatic hormone-sensitive prostate cancer
    Kuronya Zsofia
    Biro Krisztina
    Geczi Lajos
    Maraz Aniko
    ORVOSI HETILAP, 2018, 159 (41) : 1664 - 1671
12345